Anti-Xa activity of fixed-dose fondaparinux in underweight patients with acute coronary syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20171004001

Enrollment

Unknown

Registered

2017-10-04

Start date

2017-04-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndromes without ST&#45

Interventions

The first arm is fondaparinux in underweight patients (body weight < 60 kg) in patients with NSTE&#45

ACS.,The second arm is fondaparinux in normal weight patients (â‰¥60 kg) in patients with NSTE&#45

ACS.

Active Comparator Drug,Active Comparator Drug

fondaparinux A,fondaparinux B

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patientsâ€™ age â‰¥18 years, present with NSTE-ACS admitted in Maharaj Nakorn Chiang Mai hospital and receive 2.5 mg subcutaneous injection of fondaparinux and gave consent.

Exclusion criteria

Exclusion criteria: Patients with severe renal impairment (eGFR is <20 mL/min/1.73m2) Patients who receive Unfractionated heparin (UFH) or enoxaparin within 24 hours Patients with active bleeding Patients who refuse to obtain informed consent

Design outcomes

Primary

Measure	Time frame
Anti-Xa activity 24 hours Anti-Xa activity level	—

Secondary

Measure	Time frame
Bleeding event 24 hours According to Bleeding Academic Research Consortium	—

Countries

Thailand

Contacts

Public ContactWanwarang Wongcharoen

Faculty of Medicine, Chiang Mai University

bwanwarang@yahoo.com+66 5393 6716

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Anti&#45;Xa activity of fixed&#45;dose fondaparinux in underweight patients with acute coronary syndrome